The risk for OAB is greatest in Americans that are 65 and older. The population in this age bracket expects to increase by 20.9 percent, from 38.7 million in 2008 to 46.8 million in 2015. Additionally, the U.S. Census Bureau reports the fastest growing segment of the population to be aged 85 and above.
New analysis from Frost & Sullivan (pharma.frost.com), Overactive Bladder Market, finds the market earned revenues of over $1.6 billion in 2008, and estimates this to reach $2.94 billion in 2015. The study covers Detrol, Detrol LA, Ditropan, Ditropan XL, Enablex, Oytrol, Sanctura, Sanctura XR, VESIcare, and other emerging therapies.
If you are interested in more information on this study, please send an email to Johanna Haynes, Corporate Communications, at johanna.haynes[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.
"Currently, all of the FDA approved medications for the treatment of OAB are in the same class of drugs, and patients who cannot take these drugs are excluded from all medicinal options," says Frost & Sullivan Research Analyst Katheryn Symank. "Innovative therapies that are in a new class and address unmet needs have the potential to expand the OAB treatment market."
One new product, Mirabegron, utilizes a novel therapeutic approach making it. the first in a new class of medications for the treatment of OAB. This product will soon be available in the U.S. market in 2012.
Regardless of the fact that it is highly prevalent, OAB remains an underdiagnosed disorder. Patients with OAB wrongly assume treatment options are not available, or that OAB is a normal part of the aging process. As a result, large portions of those having this condition opt to suffer in silence.
Another issue contributing to the relatively low diagnosis rate for OAB is the lack of screening for this condition. The highly undiagnosed rate for OAB could hinder market development, and may impede its growth.
Although OAB is a relatively new term, there are several treatment options available. Many patients diagnosed with OAB are elderly and take multiple medications, causing concern about the risk of adverse effects from potential drug-drug interactions; therefore, most physicians do not initially use medications to treat this condition. The patient is advised to first try other treatments like physical therapy, behavioral therapy, or lifestyle modifications. Prescription medications are only used as a last resort.
Many physicians try to minimize the number of prescriptions for geriatric patients, keeping those with the highest critical return on investment (ROI) for the patient. Factors that define OAB medications as second-line therapies are marginal effectiveness and the lack of studies that compare drugs to other types of therapies. Going forward, efforts must intensify to spread awareness on the effective treatment options available for OAB.
"The availability of some popular commercials for medications that treat OAB has helped raise the awareness quotient with regard to this disorder," says Symank. "Not only do these advertisements bring this embarrassing condition to the mainstream, but they also help destigmatize it."
U.S. Overactive Bladder Market is part of the Pharmaceutical & Biotechnology Growth Partnership Services program, which also includes research in the following markets: U.S. Injectable Drug Pipeline and Global Vaccines Market. All research services included in the subscriptions provide detailed market opportunities and industry trends that were evaluated after extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.
U.S. Overactive Bladder Market / N695